Series TO 2 Warrant Recalculation Following Rights Issue “`

78a13171167934c2883cf1dfa16d3be8 2 Recalculation of warrants of series TO 2 following rights issue

STOCKHOLM, Jan. 27, 2025Following a rights issue and in line with the terms for its series TO 2 warrants (issued during the April 2024 capital raise), SciBase Holding AB (SciBase) has recalculated the number of shares per warrant and the subscription price. This recalculation, prompted by the unit rights issue announced on November 12, 2024, confirms no change. Each series TO 2 warrant remains valid for subscribing to one share at SEK 0.42, as previously stated.

Each series TO 2 warrant allows the holder to subscribe for one new SciBase share between April 3, 2029, and April 17, 2029, inclusive. The subscription price per share remains SEK 0.42.

Complete warrant terms, including potential adjustments for future share issuances, are available on SciBase’s website.

For further information, please contact:
Pia Renaudin, CEO, tel. +46732069802, e-mail:  

This announcement was distributed at 08.00 CET on January 27, 2025.

Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: 

About SciBase

SciBase is a global medical technology company focused on early detection and prevention in dermatology. We develop and market Nevisense, a point-of-care platform using AI and EIS technology to improve diagnostic accuracy for proactive skin health management.

Our mission is to minimize patient suffering and improve lives through early detection and intervention, while also reducing healthcare costs.

Founded on over 20 years of research at the Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological innovation.

Listed on Nasdaq First North Growth Market since June 2, 2015, SciBase’s Certified Advisor is Carnegie Investment Bank AB (publ). More information is available at . All press releases and financial reports are accessible at: .

This information was brought to you by Cision

The following files are available for download:

Press release recalculation TO 2 – Eng

 

elong